Prostate Cancer Treatment Advances

• Lutetium-177 PSMA Therapy: Extends survival in advanced-stage cases

• Darolutamide: Approved for non-metastatic, castration-resistant prostate cancer

• PARP Inhibitors (e.g., Olaparib): Effective in BRCA-positive patients

2025 Highlight:

“Patients receiving 177Lu-PSMA-617 had a 38% reduction in risk of death compared to standard care.”
Source: European Urology, 2025

• Castration-resistant prostate cancer (CRPC) patients

• BRCA mutation carriers

• Metastatic patients post-chemotherapy

References:

• Prostate Cancer Targeted Therapy Update – European Urology, 2025

• Real-World Impact of Darolutamide in nmCRPC – JAMA Oncology, 2025

• PARP Inhibition in BRCA-Mutated mCRPC – Cancer Discovery, 2025